Belite Bio (BLTE) Q1 FY26 earnings call

Belite Bio is transitioning to a commercial-stage company, having initiated its NDA rolling submission for Tinlarebant in Stargardt disease and building out its commercial infrastructure. The company maintains a robust cash position to fund these activities and ongoing clinical trials, including the DRAGON II study for Japan approval and an upcoming GA interim analysis. Management expects operating expenses to continue to increase as commercialization approaches.